Advertisement

Topics

Allergan’s experimental migraine drug hits trial targets

05:37 EDT 12 Jun 2018 | PharmaTimes

Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine.

Original Article: Allergan’s experimental migraine drug hits trial targets

NEXT ARTICLE

More From BioPortfolio on "Allergan’s experimental migraine drug hits trial targets"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...